A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Study ID
NCT06512051
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced or Metastatic Non-small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR-A2102 for Injection — DRUG
    Drug: SHR-A2102 for injection.
  • Adebrelimab Injection — DRUG
    Adebrelimab injection.
  • Cisplatin injection — DRUG
    Cisplatin injection.
  • Carboplatin injection — DRUG
    Carboplatin injection.
  • Bevacizumab Injection — DRUG
    Bevacizumab injection.

Study Details

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with Adebrelimab with or without other Antitumor Therapy in Advanced or Metastatic Non-small cell lung Cancer. To explore the reasonable dosage of SHR-A2102 for Advanced or Metastatic Non-small cell lung Cancer

Key Dates

First listed
Jul 22, 2024
Start date
Jul 30, 2024
Status verified
Dec 2025
Primary completion
Oct 31, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
248 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment group A
    SHR-A2102+Adebrelimab+Cisplatin/Carboplatin
  • Experimental: Treatment group B
    SHR-A2102+Adebrelimab+Bevacizumab

Primary Outcome Measure

RP2D [ Time Frame: through phase IB completion, an average of 1 years ]

Central Contacts

Related Studies